Sanofi is a global healthcare company focused on patient needs and engaged in the research, development, manufacture, and marketing of therapeutic solutions.
Biopharma Operating Segment
The Biopharma operating segment comprises commercial operation…
Analysis
Bargain bin
Sanofi falls in the bargain bin: the price is low relative to peers, but the business metrics give reason to pause.
The price is attractive. You pay 10.2× its owner earnings: the cash an owner could take out each year, which is in the historically attractive zone. At today's price, the market is assuming roughly -3% yearly growth; analysts expect 8%. The price, in other words, assumes less than the experts do.
The trajectory is moderate and the balance sheet is sturdy. The company scores 16/20 on our value-creation score: strong value creator.
Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.
360° rank · history
1007550250
Jan 202360
100
2023202420252026
All-time high
100
Jun 2026
All-time low
47
Mar 2024
Average rank
80
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
80
50
61
71
Price/Earnings
62
86
86
87
Price/Book
82
79
88
78
Dividend Yield
95
96
90
92
Value (overall)
95
98
96
100
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.